Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program

Javier Jimenez; Eran C. Gwillim; Cory Kosche; Anna Figueiredo; Corrine Rauck; Stephanie M. Rangel; Jennifer Choi; Dennis P. West; Beatrice Nardone; Mario E. Lacouture

doi:10.1016/j.jaad.2020.01.059

Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program

Javier Jimenez, Eran C. Gwillim, Cory Kosche, Anna Figueiredo, Corrine Rauck, Stephanie M. Rangel, Jennifer Choi, Dennis P. West, Beatrice Nardone^*, Mario E. Lacouture

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	955-957
Number of pages	3
Journal	Journal of the American Academy of Dermatology
Volume	83
Issue number	3
DOIs	https://doi.org/10.1016/j.jaad.2020.01.059
State	Published - Sep 2020

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2020.01.059

Cite this

Jimenez, J., Gwillim, E. C., Kosche, C., Figueiredo, A., Rauck, C., Rangel, S. M., Choi, J., West, D. P., Nardone, B., & Lacouture, M. E. (2020). Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program. Journal of the American Academy of Dermatology, 83(3), 955-957. https://doi.org/10.1016/j.jaad.2020.01.059

Jimenez, Javier ; Gwillim, Eran C. ; Kosche, Cory ; Figueiredo, Anna ; Rauck, Corrine ; Rangel, Stephanie M. ; Choi, Jennifer ; West, Dennis P. ; Nardone, Beatrice ; Lacouture, Mario E. / Bullous disorders associated with PD-1 and PD-L1 inhibitors : Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program. In: Journal of the American Academy of Dermatology. 2020 ; Vol. 83, No. 3. pp. 955-957.

@article{bd12e50eb73a45b5a441964159244ab3,

title = "Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program",

author = "Javier Jimenez and Gwillim, {Eran C.} and Cory Kosche and Anna Figueiredo and Corrine Rauck and Rangel, {Stephanie M.} and Jennifer Choi and West, {Dennis P.} and Beatrice Nardone and Lacouture, {Mario E.}",

note = "Funding Information: Funding sources: Dr Lacouture is funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30-CA-008748.",

year = "2020",

month = sep,

doi = "10.1016/j.jaad.2020.01.059",

language = "English (US)",

volume = "83",

pages = "955--957",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "3",

}

Jimenez, J, Gwillim, EC, Kosche, C, Figueiredo, A, Rauck, C, Rangel, SM , Choi, J , West, DP , Nardone, B & Lacouture, ME 2020, 'Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program', Journal of the American Academy of Dermatology, vol. 83, no. 3, pp. 955-957. https://doi.org/10.1016/j.jaad.2020.01.059

Bullous disorders associated with PD-1 and PD-L1 inhibitors : Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program. / Jimenez, Javier; Gwillim, Eran C.; Kosche, Cory; Figueiredo, Anna; Rauck, Corrine; Rangel, Stephanie M.; Choi, Jennifer ; West, Dennis P.; Nardone, Beatrice; Lacouture, Mario E.

In: Journal of the American Academy of Dermatology, Vol. 83, No. 3, 09.2020, p. 955-957.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bullous disorders associated with PD-1 and PD-L1 inhibitors

T2 - Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program

AU - Jimenez, Javier

AU - Gwillim, Eran C.

AU - Kosche, Cory

AU - Figueiredo, Anna

AU - Rauck, Corrine

AU - Rangel, Stephanie M.

AU - Choi, Jennifer

AU - West, Dennis P.

AU - Nardone, Beatrice

AU - Lacouture, Mario E.

N1 - Funding Information: Funding sources: Dr Lacouture is funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30-CA-008748.

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85080056587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080056587&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.01.059

DO - 10.1016/j.jaad.2020.01.059

M3 - Article

C2 - 32014533

AN - SCOPUS:85080056587

VL - 83

SP - 955

EP - 957

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -

Jimenez J, Gwillim EC, Kosche C, Figueiredo A, Rauck C, Rangel SM et al. Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program. Journal of the American Academy of Dermatology. 2020 Sep;83(3):955-957. https://doi.org/10.1016/j.jaad.2020.01.059

Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this